Finance

Beta
Roʻyxatlar
Aksiyalar sektorlari
Belgilar
Belgilar
Narxi
Oʻzgartirishlar
Dinamika (%)
Trend
Avvalgi yopilish narxi
Ochish
Yuqori
Past
Hajmi
Bozor kapitali
SIXB
Materials
SIXB
Materials
SIXB
-0,71%
1 092,80
-7,77
-0,71%
—1 100,571 098,941 103,801 084,24——
SIXC
Communications
SIXC
Communications
SIXC
-0,07%
604,74
-0,41
-0,07%
—605,15605,15606,69602,76——
SIXE
Energy
SIXE
Energy
SIXE
+1,64%
1 214,80
+19,61
+1,64%
—1 195,191 204,711 221,691 204,71——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,88%
1 724,57
-15,34
-0,88%
—1 739,911 734,501 734,501 710,67——
SIXM
Financials
SIXM
Financials
SIXM
+0,14%
639,43
+0,87
+0,14%
—638,56640,21645,32638,69——
SIXR
Staples
SIXR
Staples
SIXR
+0,91%
839,15
+7,58
+0,91%
—831,57840,48844,16834,54——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1,06%
215,62
+2,26
+1,06%
—213,36213,36215,79212,77——
SIXT
Technology
SIXT
Technology
SIXT
-1,69%
3 179,52
-54,66
-1,69%
—3 234,183 171,863 195,363 145,46——
SIXU
Utilities
SIXU
Utilities
SIXU
+0,13%
936,91
+1,26
+0,13%
—935,65937,31941,44933,16——
SIXV
Health care
SIXV
Health care
SIXV
+0,24%
1 452,77
+3,51
+0,24%
—1 449,261 454,771 462,651 447,95——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,72%
2 365,18
-17,27
-0,72%
—2 382,452 371,192 380,452 362,86——
LGDN:FRA
Ligand Pharmaceuticals Inc
202,00 €
+1,00%
(+2,00) 1K
28-apr, 22:00:00 (GMT+2)  ·   EUR
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
LGDN tikeri uchun statistika yaratilmoqda...
Ochish
204,00 €
Yuqori
204,00 €
Past
202,00 €
Bozor kapitali
4,66 mlrd
Oʻrtacha hajm
3,00
Hajmi
0,00
52 haftalik eng yuqori
204,00 €
52 haftalik eng past
87,00 €
Xodimlar soni
47
Yangiliklar
Internetdagi manbalardan
Profil
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Ligand Pharmaceuticals Inc haqida
CEO-
Xodimlar soni47
Asos solingansen 1987
Bosh ofislarJupiter, Florida, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytligand.com
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad hisoboti
Daromad
Sof foyda
Barcha qiymatlar – USD
mar, 2025
iyn, 2025
sen, 2025
dek, 2025
Daromad
45,33 mln
47,63 mln
115,46 mln
59,67 mln
Sotilgan mahsulotning tannarxi
54,93 mln
9,47 mln
24,82 mln
6,50 mln
Daromad narxi
54,93 mln
9,47 mln
24,82 mln
6,50 mln
Tadqiqot va ishlanmalarga xarajatlar
-
-
-
-
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
18,80 mln
20,18 mln
28,45 mln
25,03 mln
Operatsion xarajatlar
27,06 mln
28,43 mln
36,54 mln
33,12 mln
Jami operatsion xarajatlar
81,99 mln
37,91 mln
61,36 mln
39,63 mln
Operatsion daromad
-36,66 mln
9,72 mln
54,10 mln
20,04 mln
Boshqa nooperatsion daromad
-2,06 mln
96,00 ming
390,00 ming
1,48 mln
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
-50,18 mln
11,22 mln
141,14 mln
56,78 mln
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
-37,81 mln
10,28 mln
57,45 mln
116,80 mln
Daromad soligʻi boʻyicha xarajat
-7,73 mln
6,38 mln
23,86 mln
12,00 mln
Amaldagi soliq stavkasi
15,40%
56,81%
16,91%
21,13%
Boshqa operatsion xarajatlar
-
-
-
-
Sof foyda
-42,45 mln
4,85 mln
117,27 mln
44,78 mln
Sof foyda marjasi
-93,64%
10,18%
101,57%
75,06%
Har bir aksiya foydasi
1,33
1,60
3,09
2,02
Foizlar va investitsiyalardan olingan daromadlar
1,77 mln
1,62 mln
3,87 mln
6,39 mln
Foizlarni toʻlash xarajatlari
-867,00 ming
-1,15 mln
-910,00 ming
-1,78 mln
Foizlarni toʻlash boʻyicha sof xarajatlar
904,00 ming
468,00 ming
2,96 mln
4,61 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
-28,35 mln
17,82 mln
63,26 mln
28,25 mln
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-
-
AI kontentda xatolar boʻlishi mumkin. Batafsil
YordamFikr-mulohazaMaxfiylikShartlarMajburiyatlardan voz kechish

Tahlil

Vazifalarim
Hali vazifa yaratmagansiz
Vazifalaringiz shu yerda chiqadi. Vazifalarni rejalashtiring va Google Finance xizmatidan foydalaning.
Andozalar
Kuzatuv roʻyxati brifingi
Kuzatuv roʻyxatining kunlik bozor oldidan tahlili
Kelgusi tushumlar
Hafta ichida kelgusi tushum hisobotlari
Anomal volatillik va hajm
Bugun erta ogohlantirish: volatillik va hajm
AI kontentda xatolar boʻlishi mumkin. Batafsil
YordamFikr-mulohazaMaxfiylikShartlarMajburiyatlardan voz kechish